Hybrid PET/CT enhanced with intravenous CT contrast deserves wider acceptance and adoption, as diagnostically optimized CT can complement PET—and vice versa—for a variety of potential indications. That’s one opinion on the matter.

For 45% to 47% of patients who were deemed negative after conventional baseline scans, the use of the radiohybrid imaging agent resulted in at least one true positive PET finding

The study, which followed 195 patients recently diagnosed with multiple myeloma (MM), found that a negative PET/CT scan six months after diagnosis and induction therapy was significantly linked with improved survival.

The new equipment, which initially will be used to treat prostate and neuroendocrine tumors, is expected to be operational in July.

In pediatric care settings, hybrid PET/MR imaging combines “exquisite soft-tissue information obtained by MR imaging with functional information provided by PET.”

The FDA has approved a lab test for evaluating cognitively impaired adults who may be in the early stages of Alzheimer’s disease.

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested.